[1] Molfino A, Amabile MI, Monti M, et al.Omega-3 Polyunsaturated Fatty Acids in Critical Illness: Anti-Inflammatory, Proresolving, or Both?. Oxid Med Cell Longev. 2017;2017:5987082.[2] Uddin M, Levy BD.Resolvins: natural agonists for resolution of pulmonary inflammation.Prog Lipid Res.2011;50(1):75-88.[3] Balta MG, Loos BG, Nicu EA. Emerging Concepts in the Resolution of Periodontal Inflammation: A Role for Resolvin E1. Front Immunol. 2017;8:1682. [4] Spite M,Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res. 2010; 107(10):1170-1184.[5] Haas-Stapleton EJ,Yan L,Song H,et al.Candida albicansModulates Host Defense by Biosynthesizing the Pro-Resolving Mediator Resolvin E1.Plos One.2007;2(12):e1316.[6] Arita M,Bianchini F,Aliberti J,et al.Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1.J exp med.2005;201(5):713-722.[7] Alessi DR,Caudwell FB,Andjelkovic M,et al. Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett.1996;399(3): 333-338.[8] Loos BG,Papantonopoulos G,Jepsen S,et al.What is the Contribution of Genetics to Periodontal Risk?. Dent Clin North Am. 2015;59(4):761-780.[9] Da YO,Talukdar S,Bae EJ,et al.GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing Effects.Cell.2010;142(5):687-698.[10] Dai J,Bi L, Lin J, et al. Evaluation of interleukin-10 producing CD19+ B cells in human gingival tissue. Arch Oral Biol. 2017;84: 112-117.[11] Roberts HM,Ling MR,Insall R,et al.Impaired neutrophil directional chemotactic accuracy in chronic periodontitis patients.J Clin Periodontol. 2015;42(1):1-11.[12] Arita M,Yoshida M,Hong S,et al.Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A.2005;102(21):7671-7676.[13] Hajishengallis E, Hajishengallis G.Neutroph IL. Neutrophil homeostasis and periodontal health in children and adults. J Dent Res. 2014;93(3): 231-237. [14] Fredman G, Oh SF, Ayilavarapu S, et al.Impaired phagocytosis in localized aggressive periodontitis: rescue by Resolvin E1.PLoS One. 2011;6(9):e24422.[15] Dona M,Fredman G,Schwab JM, et al.Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets.Blood.2008;112(3):848.[16] Lee CT,Teles R, Kantarci A,et al.Resolvin E1 Reverses Experimental Periodontitis and Dysbiosis. J Immunol. 2016;197(7):2796-2806. [17] Fredman G,Dyke T E V, Serhan CN. Resolvin E1 regulates adenosine diphosphate activation of human platelets.Arterioscler Thromb Vasc Biol. 2010;30(10):2005-2013.[18] Arvanitidis E,Bizzarro S,Rodriguez EA,et al.Reduced platelet hyper-reactivity and platelet-leukocyte aggregation after periodontal therapy. Thromb J. 2017;15:5. [19] Laky M,Anscheringer I,Wolschner L,et al.Periodontal treatment limits platelet activation in patients with periodontitis -a controlled- randomized intervention trial. J Clin Periodontol. 2018;45(9): 1090-1097.[20] Henry MN, Peter S, Harald FL. Platelets in inflammation and at herogenesis.FrontImmunol.2015; 6(98):1-11. [21] Hajishengallis G,Moutsopoulos NM,Hajishengallis E,et al. Immune and regulatory functions of neutrophils in inflammatory bone loss.Semin Immunol. 2016;28(2):146-158.[22] Unno Y, Sato Y, Fukuda H, et al. Resolvin E1, but not resolvins E2 and E3, promotes fMLF-induced ROS generation in human neutrophils. FEBS Lett. 2018;592(16):2706-2715.[23] Hasturk H,Kantarci A,Ohira T,et al. Resolvin E1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. FASEB J.2006;20(2):401-403. [24] Ortega-Gómez A, Perretti M, Soehnlein O. Resolution of inflammation: an integrated view. EMBO Mol Med.2013;5(5): 661-674. [25] Holmström SB, Clark R,Zwicker S,et al.Gingival Tissue Inflammation Promotes Increased Matrix Metalloproteinase-12 Production by CD200R(low) Monocyte-Derived Cells in Periodontitis.J Immunol. 2017;199(12):4023-4035..[26] Italiani P,Boraschi D.From monocytes to M1/M2 macrophages: phenotypical vs. Front Immunol. 2014;5:514. [27] Van den Bossche J, Baardman J, Otto NA, et al.Mitochondrial dysfunction prevents repolarization of inflammatory macrophages. Cell Rep.2016;17(3):684–696. [28] Moutsopoulos N, Konkel J, Sarmadi M, et al. Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss.Sci Transl Med. 2014;6(229): 229ra40..[29] Davies LC,Taylor PR.Tissue-resident macrophages: then and now. Immunology.2015;144(4):541-548.[30] Gao L,Faibish D,Fredman G,et al.Resolvin E1 and chemokine-like receptor 1 mediate bone preservation. J Immunol. 2013;190(2): 689-694.[31] Crotti TN,Dharmapatni AA,Alias E,et al.Osteoimmunology:Major and Costimulatory Pathway Expression Associated with Chronic Inflammatory Induced Bone Loss. J Immunol Res. 2015;2015: 281287.[32] Bostanci N, Saygan B, Emingil G,et al.Effect of periodontal treatment on receptor activator of NF-κB ligand and osteoprotegerin levels and relative ratio in gingival crevicular fluid.J Clin Periodontol. 2011;38(5): 428-433.[33] Cerletti C,de Gaetano G,Lorenzet R.Platelet–leukocyte interactions: multiple links between inflammation, blood coagulation and vascular risk.Mediterr J Hematol Infect Dis.2010; 2(3):e2010023. |